{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:17:44Z","timestamp":1793319464570,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.tjpad.2025.100362","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T11:11:10Z","timestamp":1756552270000},"page":"100362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Early Alzheimer\u2019s disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6422-8870","authenticated-orcid":false,"given":"Jung-Lung","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-6679","authenticated-orcid":false,"given":"Kee Hyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Panegyres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao Hsien","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young In","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4456-6766","authenticated-orcid":false,"given":"Vinay","family":"Prusty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lolita Stephanie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yat Fung","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100362_bib0001","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100362_bib0002","unstructured":"Lecanemab Prescribing Information. https:\/\/www.leqembi.com\/-\/media\/Files\/Leqembi\/Prescribing-Information.pdf. Accessed January 2024."},{"key":"10.1016\/j.tjpad.2025.100362_bib0005","unstructured":"Eisai. \u201cLEQEMBI\u00ae\u201d (lecanemab) approved for the treatment of Alzheimer\u2019s disease in South Korea. https:\/\/www.eisai.com\/news\/2024\/news202436.html. Accessed July 2024."},{"key":"10.1016\/j.tjpad.2025.100362_bib0006","unstructured":"Eisai. \u201cLEQEMBI\u00ae\u201d (lecanemab) approved for the treatment of Alzheimer\u2019s disease in Hong Kong. https:\/\/www.eisai.com\/news\/2024\/news202449.html. Accessed January 2025."},{"key":"10.1016\/j.tjpad.2025.100362_bib0007","unstructured":"Eisai. Update on regulatory review of lecanemab for early Alzheimer\u2019s disease by the European commission. https:\/\/www.eisai.com\/news\/2025\/news202531.html. Accessed June 2025."},{"key":"10.1016\/j.tjpad.2025.100362_bib0008","unstructured":"Taiwan Food and Drug Administration. Lecanemab. https:\/\/lmspiq.fda.gov.tw\/web\/DRPIQ\/DRPIQ1000Result?licBaseId=CC7DDD77-4B0D-4DF5-BD9C-95CD54F721BA. Accessed 25 June 2025."},{"key":"10.1016\/j.tjpad.2025.100362_bib0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.12779\/dnd.2024.23.4.165","article-title":"Lecanemab: appropriate use recommendations by Korean dementia association","volume":"23","author":"Park","year":"2024","journal-title":"Dement Neurocogn Disord"},{"key":"10.1016\/j.tjpad.2025.100362_bib0011","unstructured":"Australian Government 2025. TGA confirms decision to not register lecanemab (LEQEMBI) published March 3 2025. https:\/\/www.tga.gov.au\/news\/news\/tga-confirms-decision-not-register-lecanemab-leqembi. Accessed May 2025."},{"key":"10.1016\/j.tjpad.2025.100362_bib0012","unstructured":"Taiwan Food and Drug Administration. Donanemab. https:\/\/lmspiq.fda.gov.tw\/web\/DRPIQ\/DRPIQ1000Result?licBaseId=21025D05-6A85-4BD2-B491-218987607AA0 Accessed 25 June 2025."},{"key":"10.1016\/j.tjpad.2025.100362_bib0015","unstructured":"Eli Lilly. Donanemab prescribing information. https:\/\/pi.lilly.com\/us\/kisunla-uspi.pdf. Accessed July 2024."},{"key":"10.1016\/j.tjpad.2025.100362_bib0016","unstructured":"United Arab Emirates Ministry of Health and Prevention. Product marketing authorization approval: Kisunla\u2122 350 mg\/20 mL. https:\/\/smartservices.moh.gov.ae\/eReports\/downloadCertificate?appNumber=0F6A88C55CC68BAD01E74FB0611B9875. Accessed January 2025."},{"key":"10.1016\/j.tjpad.2025.100362_bib0017","unstructured":"Donanemab SmPC. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/023d485b567facc9afc0b4f131b92e36e3696cdd Accessed November 2024."},{"key":"10.1016\/j.tjpad.2025.100362_bib0018","unstructured":"Eli Lilly. Lilly's Kisunla\u2122 (donanemab-azbt) approved in China for the treatment of early symptomatic Alzheimer's disease. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-kisunlatm-donanemab-azbt-approved-china-treatment-early#:~:text=17%2C%202024%20%2FPRNewswire%2F%20%2D%2D,treatment%20for%20adults%20with%20early. Accessed January 2025."},{"key":"10.1016\/j.tjpad.2025.100362_bib0019","unstructured":"Alzheimer\u2019s Disease International. Dementia statistics. Available at: https:\/\/www.alzint.org\/about\/dementia-facts-figures\/dementia-statistics\/#:~:text=Numbers%20of%20people%20with%20dementia,will%20be%20in%20developing%20countries. Accessed November 2023."},{"issue":"3","key":"10.1016\/j.tjpad.2025.100362_bib0020","first-page":"219","article-title":"China Alzheimer Report","volume":"23","author":"Wang","year":"2024","journal-title":"Zhenduanxue lilun yu shijian"},{"key":"10.1016\/j.tjpad.2025.100362_bib0021","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/ijerph16010128","article-title":"Perceptions of Chinese towards dementia in Hong Kong\u2014Diagnosis, symptoms and impacts","volume":"16","author":"Lam","year":"2019","journal-title":"Int J Env Res Public Health"},{"key":"10.1016\/j.tjpad.2025.100362_bib0022","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/1533317507312624","article-title":"The Japanese MCI screen for early detection of Alzheimer's disease and related disorders","volume":"23","author":"Cho","year":"2008","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.tjpad.2025.100362_bib0023","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1186\/s12877-021-02526-x","article-title":"Health-economic burden of dementia in South Korea","author":"Shon","year":"2021","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.tjpad.2025.100362_bib0024","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global burden of disease study 2019","volume":"7","year":"2022","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.tjpad.2025.100362_bib0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/ADR-200263","article-title":"Diagnosis of Alzheimer's disease in developed and developing countries: systematic review and meta-analysis of diagnostic test accuracy","volume":"5","author":"Ch\u00e1vez-Fumagalli","year":"2021","journal-title":"J Alzheimers Dis Rep"},{"key":"10.1016\/j.tjpad.2025.100362_bib0026","first-page":"876","volume":"23","author":"Watson","year":"2023"},{"key":"10.1016\/j.tjpad.2025.100362_bib0029","series-title":"The Australian Dementia Network (ADNeT) Registry 2022 Annual report","author":"Ward","year":"2023"},{"key":"10.1016\/j.tjpad.2025.100362_bib0030","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1016\/S2468-2667(20)30185-7","article-title":"Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study","volume":"5","author":"Jia","year":"2020","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.tjpad.2025.100362_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.37819\/hb.3.1771","article-title":"2023 China Alzheimer\u2019s disease: facts and figures","volume":"2","author":"Xiao","year":"2023","journal-title":"Hum Brain"},{"key":"10.1016\/j.tjpad.2025.100362_bib0032","article-title":"Geographical variation in dementia prevalence across China: a geospatial analysis","volume":"47","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.tjpad.2025.100362_bib0033","series-title":"Dementia Friendly Community Campaign","year":"2018"},{"key":"10.1016\/j.tjpad.2025.100362_bib0034","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3233\/JAD-215312","article-title":"Demographics and medication use of patients with late-onset Alzheimer\u2019s disease in Hong Kong","volume":"87","author":"Wong","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100362_bib0038","doi-asserted-by":"crossref","first-page":"462","DOI":"10.14283\/jpad.2021.38","article-title":"Editorial: Alzheimer's disease research in Japan: A short history, current status and future perspectives toward prevention","volume":"8","author":"Iwatsubo","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100362_bib0039","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1186\/s12877-021-02540-z","article-title":"Future projections of the prevalence of dementia in Japan: results from the Toyama dementia survey","volume":"21","author":"Nakahori","year":"2021","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.tjpad.2025.100362_bib0040","doi-asserted-by":"crossref","first-page":"962","DOI":"10.5692\/clinicalneurol.52.962","article-title":"Prevalence of dementia in Japan: past, present and future","volume":"52","author":"Asada","year":"2012","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.tjpad.2025.100362_bib0041","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CEOR.S146788","article-title":"Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer's disease in Japan","volume":"10","author":"Montgomery","year":"2017","journal-title":"Clin Outcomes Res"},{"key":"10.1016\/j.tjpad.2025.100362_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-062304","article-title":"Dementia prevalence estimation among the main ethnic groups in New Zealand: a population-based descriptive study of routinely collected health data","volume":"12","author":"Cheung","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.tjpad.2025.100362_bib0043","author":"Ma\u2019u"},{"key":"10.1016\/j.tjpad.2025.100362_bib0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3988\/jcn.2021.17.2.249","article-title":"Prevalence and incidence of dementia in South Korea: a nationwide analysis of the national health insurance service senior cohort","volume":"17","author":"Jang","year":"2021","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.tjpad.2025.100362_bib0046","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5535\/arm.22027","article-title":"Dementia epidemiology fact Sheet 2022","volume":"46","author":"Shin","year":"2022","journal-title":"Ann Rehabil Med"},{"key":"10.1016\/j.tjpad.2025.100362_bib0048","article-title":"Gender and age differences and the trend in the incidence and prevalence of dementia and Alzheimer's disease in Taiwan: A 7-year national population-based study","author":"Liu","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.tjpad.2025.100362_bib0049","first-page":"S73","article-title":"Integrated care for dementia in Taiwan: policy, system and services","author":"Hsiao","year":"2019","journal-title":"Int J Gerontol Spec Issue"},{"key":"10.1016\/j.tjpad.2025.100362_bib0050","article-title":"A nationwide survey of mild cognitive impairment and dementia, including very mild dementia, in Taiwan","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tjpad.2025.100362_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2024.105330","article-title":"Trends in dementia incidence and mortality, and dynamic changes in comorbidity and healthcare utilization from 2004 to 2017: A Taiwan national cohort study","volume":"121","author":"Huang","year":"2024","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.tjpad.2025.100362_bib0053","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3233\/JAD-200509","article-title":"Alzheimer\u2019s disease and its related dementias among Asian Americans, Native Hawaiians, and Pacific Islanders: A scoping review","volume":"77","author":"Lim","year":"2020","journal-title":"J Alzheimer 19s Dis"},{"key":"10.1016\/j.tjpad.2025.100362_bib0055","article-title":"Climate change in Western Australia and its potential impact on human health","volume":"12","author":"Teasdale","year":"2023","journal-title":"J Clim Change Health"},{"key":"10.1016\/j.tjpad.2025.100362_bib0056","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/01.wnl.0000262028.16738.64","article-title":"Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE","volume":"68","author":"Galasko","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100362_bib0057","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jalz.2016.06.2360","article-title":"Systematic review of dementia prevalence and incidence in United States race\/ethnic populations","volume":"13","author":"Mehta","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100362_bib0058","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3233\/JAD-151089","article-title":"The role of ethnicity in Alzheimer\u2019s disease: findings from the C-PATH Online Data repository","volume":"51","author":"Chen","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100362_bib0059","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100362_bib0060","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International working group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100362_bib0061","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","article-title":"Alzheimer disease as a clinical-biological construct-an International Working Group recommendation","volume":"1","author":"Dubois","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100362_bib0062","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s40120-023-00504-6","article-title":"A systematic review of clinical practice guidelines for Alzheimer\u2019s disease and strategies for future advancements","volume":"12","author":"Monfared","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.tjpad.2025.100362_bib0063","doi-asserted-by":"crossref","first-page":"42","DOI":"10.12779\/dnd.2022.21.1.42","article-title":"Clinical Practice Guideline for dementia (Diagnosis and Evaluation): 2021 revised edition","volume":"21","author":"Lee","year":"2022","journal-title":"Dement Neurocogn Disord"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100362_bib0064","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/wjtcm.wjtcm_28_21","article-title":"Xinjiang uygur autonomous region hospital of traditional Chinese Medicine, et al. International clinical practice guideline of Chinese medicine Alzheimer","volume":"7","year":"2021","journal-title":"World J Tradit Chin Med"},{"key":"10.1016\/j.tjpad.2025.100362_bib0065","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jfma.2024.01.018","article-title":"Application of blood-based biomarkers of Alzheimer\u2019s disease in clinical practice: recommendations from Taiwan Dementia society","volume":"123","author":"Cheng","year":"2024","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.tjpad.2025.100362_bib0066","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2023-101310","article-title":"Consensus on rapid screening for prodromal Alzheimer\u2019s disease in China","volume":"37","author":"Huang","year":"2024","journal-title":"Gen Psychiatr"},{"key":"10.1016\/j.tjpad.2025.100362_bib0067","series-title":"Evidence-Based Clinical Practice Guideline For Deprescribing Cholinesterase Inhibitors And Memantine: Recommendations","author":"Reeve","year":"2018"},{"key":"10.1016\/j.tjpad.2025.100362_bib0068","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5694\/mja2.50015","article-title":"Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary","volume":"210","author":"Reeve","year":"2019","journal-title":"Med J Aust"},{"key":"10.1016\/j.tjpad.2025.100362_bib0069","first-page":"292","article-title":"Taiwan Dementia Treatment Guideline","volume":"15","author":"Huang","year":"2021","journal-title":"Int J Gerontol"},{"key":"10.1016\/j.tjpad.2025.100362_bib0070","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","article-title":"Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology","volume":"90","author":"Petersen","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100362_bib0071","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00415-019-09506-7","article-title":"Cognitive assessment tools for mild cognitive impairment screening","volume":"268","author":"Zhuang","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.tjpad.2025.100362_bib0072","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3233\/JAD-220288","article-title":"Nationally informed recommendations on approaching the detection, assessment, and management of mild cognitive impairment","volume":"89","author":"Woodward","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100362_bib0074","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5694\/mja2.51880","article-title":"Assessing preparedness for Alzheimer disease-modifying therapies in Australasian health care systems","volume":"218","author":"Brodtmann","year":"2023","journal-title":"Med J Aust"},{"key":"10.1016\/j.tjpad.2025.100362_bib0076","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/diagnostics6010006","article-title":"Early dementia screening","volume":"6","author":"Panegyres","year":"2016","journal-title":"Diagnostics"},{"key":"10.1016\/j.tjpad.2025.100362_bib0077","first-page":"3615","article-title":"Expert consensus on the application of amyloid-PET imaging in the diagnosis of Alzheimer's disease","volume":"103","year":"2023","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.tjpad.2025.100362_bib0078","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12875-022-01716-9","article-title":"Knowledge, attitudes, and practice of general practitioners toward community detection and management of mild cognitive impairment: a cross-sectional study in Shanghai, China","volume":"23","author":"Lu","year":"2022","journal-title":"BMC Prim Care"},{"key":"10.1016\/j.tjpad.2025.100362_bib0079","first-page":"327","article-title":"Impact of 18FDG PET and 11C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong","volume":"22","author":"Shea","year":"2016","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.tjpad.2025.100362_bib0080","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3233\/JAD-131868","article-title":"Combination of MRI hippocampal volumetry and arterial spin labeling MR perfusion at 3-tesla improves the efficacy in discriminating Alzheimer's disease from cognitively normal elderly adults","volume":"41","author":"Mak","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100362_bib0081","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/1533317513504615","article-title":"Cerebrospinal fluid biomarkers of Alzheimer's disease in Chinese patients: a pilot study","volume":"28","author":"Shea","year":"2013","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.tjpad.2025.100362_bib0082","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/alz.13676","article-title":"A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups","volume":"20","author":"Jiang","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100362_bib0085","series-title":"Practical Manual of Dementia in Older Adults","year":"2022"},{"key":"10.1016\/j.tjpad.2025.100362_bib0086","first-page":"579","article-title":"The first case series of Chinese patients in Hong Kong with familial Alzheimer's disease compared with those with biomarker-confirmed sporadic late-onset Alzheimer's disease","volume":"23","author":"Shea","year":"2017","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.tjpad.2025.100362_bib0087","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-201184","article-title":"Mild behavioral impairment and subjective cognitive decline predict cognitive and functional decline","volume":"80","author":"Ismail","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100362_bib0088","author":"Pan"},{"key":"10.1016\/j.tjpad.2025.100362_bib0092","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1177\/00048674221121091","article-title":"Anti-dementia medication use in Aotearoa New Zealand: an exploratory study using health data from the Integrated Data Infrastructure (IDI)","volume":"57","author":"Chan","year":"2023","journal-title":"Aust N Z J Psychiatr"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100362_bib0093","doi-asserted-by":"crossref","first-page":"758","DOI":"10.5124\/jkma.2018.61.12.758","article-title":"Pharmacotherapy for dementia","volume":"61","author":"Youn","year":"2018","journal-title":"J Korean Med Assoc"},{"key":"10.1016\/j.tjpad.2025.100362_bib0094","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4235\/agmr.20.0082","article-title":"Is Korea prepared for an Alzheimer\u2019s disease-modifying therapy? Assessing the Korean healthcare system infrastructure and the effect of blood-based biomarker tests","volume":"25","author":"Jun","year":"2021","journal-title":"Ann Geriatr Med Res"},{"key":"10.1016\/j.tjpad.2025.100362_bib0095","doi-asserted-by":"crossref","first-page":"174","DOI":"10.17079\/jkgn.2303.16001","article-title":"A comparison of dementia care and policy in five Asian regions: A literature review","volume":"25","author":"Kang","year":"2023","journal-title":"J Korean Gerontol Nurs"},{"key":"10.1016\/j.tjpad.2025.100362_bib0096","unstructured":"Australian Institute of Health and Welfare. Dementia in Australia. National policy response to dementia. Last updated September 13 2024. https:\/\/www.aihw.gov.au\/reports\/dementia\/dementia-in-aus\/contents\/national-policy-response-to-dementia. Accessed May 2025."},{"key":"10.1016\/j.tjpad.2025.100362_bib0097","series-title":"Dementia in Australia","year":"2024"},{"key":"10.1016\/j.tjpad.2025.100362_bib0098","first-page":"715","article-title":"2024 Chinese expert consensus on the diagnosis and treatment of mild cognitive impairment due to AD","volume":"57","author":"Chen","year":"2024","journal-title":"Chin J Neurol"},{"key":"10.1016\/j.tjpad.2025.100362_bib0099","unstructured":"The Government of the Hong Kong Special Administrative Region. Press release. June 2022. LCQ18: policy on support for dementia patients. https:\/\/www.info.gov.hk\/gia\/general\/202206\/01\/P2022060100384.htm. Accessed May 2024."},{"key":"10.1016\/j.tjpad.2025.100362_bib0100","first-page":"492","article-title":"Alzheimer\u2019s disease: insights for risk evaluation and prevention in the Chinese population and the need for a comprehensive programme in Hong Kong\/China","volume":"24","author":"Yee","year":"2018","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.tjpad.2025.100362_bib0102","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.3346\/jkms.2023.38.e227","article-title":"Comparative analysis on the policy approaches in the national dementia plans of G7 countries and Korea and their implementation","volume":"38","author":"Seong","year":"2023","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100362_bib0103","doi-asserted-by":"crossref","first-page":"13","DOI":"10.35772\/ghm.2023.01047","article-title":"A policy overview of Japan's progress on dementia care in a super aged society and future challenges","volume":"6","author":"Ishihara","year":"2024","journal-title":"J Glob Health Med"},{"key":"10.1016\/j.tjpad.2025.100362_bib0106","unstructured":"Ministry of Health and Welfare. The 3rd national dementia plan. https:\/\/www.alzint.org\/u\/Republic-of-Korea-The-3rd-National-Dementia-Plan.pdf. Accessed November 2023."},{"key":"10.1016\/j.tjpad.2025.100362_bib0107","unstructured":"Taiwan Government Ministry of Health and Welfare. Promoting the \u201cTaiwan dementia policy: a framework for prevention and care 2.0\u201d to jointly create a \u201cdementia-friendly Taiwan!\u201d https:\/\/www.mohw.gov.tw\/cp-3775-43174-2.html Accessed May 2024."},{"key":"10.1016\/j.tjpad.2025.100362_bib0109","unstructured":"IREACH. Battling dementia in Native and Pacific Islander communities. https:\/\/ireach.wsu.edu\/near\/. Accessed June 2024."},{"key":"10.1016\/j.tjpad.2025.100362_bib0110","article-title":"A scoping review of the unique landscape and challenges associated with dementia in the Western Pacific region","volume":"50","author":"Devenney","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.tjpad.2025.100362_bib0111","article-title":"Dementia diagnostic and treatment services in the Western Pacific: challenges, preparedness and opportunities in the face of amyloid-targeting therapies","volume":"50","author":"O\u2019Callaghan","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.tjpad.2025.100362_bib0112","article-title":"Regional health priorities for dementia: a roadmap for the Western Pacific","volume":"50","author":"Timmins","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.tjpad.2025.100362_bib0113","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2188\/jea.JE20200602","article-title":"Rural-urban disparities in the prevalence of mild cognitive impairment and dementia in Taiwan: A door-to-door nationwide study","volume":"32","author":"Liu","year":"2022","journal-title":"J Epidemiol"},{"key":"10.1016\/j.tjpad.2025.100362_bib0114","first-page":"1598","article-title":"Alzheimer\u2019s disease facts and figures","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100362_bib0115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3233\/JAD-2010-101221","article-title":"A nationwide survey on the prevalence of dementia and mild cognitive impairment in South Korea","volume":"23","author":"Kim","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100362_bib0116","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1479-8301.2007.00197.x","article-title":"Mild cognitive impairment in a population-based epidemiological study","volume":"7","author":"Ishikawa","year":"2007","journal-title":"Psychogeriatrics"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100362_bib0117","doi-asserted-by":"crossref","first-page":"24","DOI":"10.12779\/dnd.2025.24.1.24","article-title":"Clinical Practice Guidelines for dementia: recommendations for the pharmacological treatment of behavioral and psychological symptoms","volume":"24","author":"Byeon","year":"2025","journal-title":"Dement Neurocogn Disord"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100362_bib0118","doi-asserted-by":"crossref","first-page":"165","DOI":"10.12779\/dnd.2024.23.4.165","article-title":"Lecanemab: appropriate use recommendations by Korean Dementia Association","volume":"23","author":"Park","year":"2024","journal-title":"Dement Neurocogn Disord"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T23:32:18Z","timestamp":1785972738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725003048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":93,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2274580725003048"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100362","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Alzheimer\u2019s disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100362"}}